# Pain Evaluation in Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone Metastases

> **NCT02398526** · — · COMPLETED · sponsor: **Bayer** · enrollment: 363 (actual)

## Conditions studied

- Castration-Resistant Prostatic Cancer

## Interventions

- **DRUG:** Radium-223 dichloride, (Xofigo, BAY88-8223)

## Key facts

- **NCT ID:** NCT02398526
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-19
- **Primary completion:** 2020-05-20
- **Final completion:** 2020-07-15
- **Target enrollment:** 363 (ACTUAL)
- **Last updated:** 2021-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02398526

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02398526, "Pain Evaluation in Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone Metastases". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02398526. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*